Evidence map›Paper›PMID 39803823›Full record

ArticleMacromolecular bioscience2025

Enhancing Hemocompatibility in ECMO Systems With a Fibrinolytic Interactive Coating: in Vitro Evaluation of Blood Clot Lysis Using a 3D Microfluidic Model.

Lena Witzdam, Samarth Sandhu, Suji Shin, Yeahwa Hong, Shanzeh Kamal, Oliver Grottke, Keith E Cook, Cesar Rodriguez-Emmenegger

Abstract read
In one paragraph

Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lena WitzdamInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Carrer de Baldiri Reixac, 10, 12, Barcelona, 08028, Spain.ORCID 0000-0001-8388-6756
Samarth SandhuDepartment of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Ave, Pittsburgh, PA, 15213, USA.
Suji ShinDepartment of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Ave, Pittsburgh, PA, 15213, USA.ORCID 0000-0002-8323-9919
Yeahwa HongDepartment of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Ave, Pittsburgh, PA, 15213, USA.ORCID 0000-0001-9963-6970
Shanzeh KamalDepartment of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Ave, Pittsburgh, PA, 15213, USA.
Oliver GrottkeDepartment of Anesthesiology, RWTH Aachen University Hospital, Pauwelsstr. 30, 52074, Aachen, Germany.ORCID 0000-0002-0722-3122
Keith E CookDepartment of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Ave, Pittsburgh, PA, 15213, USA.ORCID 0000-0002-5604-3718
Cesar Rodriguez-EmmeneggerInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Carrer de Baldiri Reixac, 10, 12, Barcelona, 08028, Spain.ORCID 0000-0003-0745-0840

Funding

Bundesministerium für Bildung und Forschung 031B1154BDeutsche Forschungsgemeinschaft 346972946DEVCOM Army Research Laboratory W911NF-20-2-0175European Innovation CouncilHORIZON EUROPE European Innovation Council 101115545Institutional Review Board of Carnegie Mellon University STUDY2021_00000488
6 · The paper itself

Abstract

Blood-contacting medical devices, especially extracorporeal membrane oxygenators (ECMOs), are highly susceptible to surface-induced coagulation because of their extensive surface area. This can compromise device functionality and lead to life-threatening complications. High doses of anticoagulants, combined with anti-thrombogenic surface coatings, are typically employed to mitigate this risk, but such treatment can lead to hemorrhagic complications. Therefore, bioactive surface coatings that mimic endothelial blood regulation are needed. However, evaluating these coatings under realistic ECMO conditions is both expensive and challenging. This study utilizes microchannel devices to simulate ECMO fluid dynamics and assess the clot-lysis efficacy of a self-activating fibrinolytic coating system. The system uses antifouling polymer brushes combined with tissue plasminogen activator (tPA) to induce fibrinolysis at the surface. Here, tPA catalyzes the conversion of blood plasminogen into plasmin, which dissolves clots. This positive feedback loop enhances clot digestion under ECMO-like conditions. This findings demonstrate that this coating system can significantly improve the hemocompatibility of medical device surfaces.

Indexed as

Blood CoagulationCoated Materials, BiocompatibleExtracorporeal Membrane OxygenationFibrinolysisLab-On-A-Chip DevicesThrombosisHumansMaterials TestingTissue Plasminogen ActivatorCoated Materials, BiocompatibleTissue Plasminogen Activator3D printingantifouling polymer brushesextracorporeal membrane oxygenatorfibrinolytic coatingtissue plasminogen activator

Identifiers

PMID39803823
PMCPMC12080294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.